QT Imaging Holdings (OTCQB: QTIH) has announced that it has entered into an exclusive distribution agreement for its QTI Breast Acoustic CT scanners and QTI Cloud Platform in the United Arab Emirates (UAE) with closely held Al Naghi Medical (NMC), a leading distributor of medical devices.
The agreement provides for committed, minimum order quantities of seven scanners in 2026 (starting in the second quarter), increasing to 16 scanners in 2027 and 20 scanners in 2028, for a total minimum of 43 scanners and revenue of more than $24 million.
In a statement, Dr. Raluca Dinu, CEO of QTI, commented, “We are excited to gain access to this significant market by partnering for the distribution of our technology with NMC, one of the leading medical device distributors in the UAE. By making breast imaging accurate, comfortable, and stress-free, we believe that our QTI Breast Acoustic CT scanner can help change the current breast cancer screening paradigm in the UAE, promoting earlier detection and improved prognoses.”
The FDA-cleared QTI Breast Acoustic CT scanner is the first non-invasive breast imaging technology that provides a true 3D image of the breast anatomy without compression, contrast administration, or harmful ionizing radiation. The company also recently unveiled its ongoing strategic initiative to build the QTI Cloud Platform, designed to transform breast health through biomarkers and imaging intelligence. Utilizing a tiered Software as a Service (SaaS) delivery model, the QTI Cloud SaaS Platform will provide subscribers with access to a large and growing portfolio of tools that automate findings classification, deliver consistent decision support, and ensure that future AI/ML advancements, such as automated lesion segmentation, volumetric tissue characterization, and computer-aided diagnosis and reporting, can be securely delivered to all securely connected QTI Breast Acoustic CT systems without requiring on-premise updates.
The prevalence of breast cancer in the UAE has increased dramatically throughout the decades. According to national data cited by Elobaid et al., breast cancer accounts for 25% of cancer cases diagnosed in the UAE, and 43% of cancer cases diagnosed in women in the UAE. Of note, according to data cited by Al-Shamsi and Alrawi (2018), the median age of breast cancer diagnosis in the UAE is approximately 48–49 years, which previous studies cited by Rabbani et al. indicate is nearly a decade younger than in Western countries. As genetic predisposition, particularly BRCA1 and BRCA2 mutations, has been identified as an important contributor to breast cancer risk in the UAE, QT Imaging breast imaging technology providing a solution for younger women is well suited for this market.
